SLLK-Control-Peptide-for-TSP1-Inhibitor-TFA - Peptide - 生命科學(xué)試劑 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemESLLK, Control Peptide for TSP1 Inhibitor(TFA)Cat. No.: HY-P0301A分式: CHFNO分量: 573.6Sequence: Ser-Leu-Leu-Lys-NH2Sequence Shortening: SLLK-NH2作靶點(diǎn): Others作通路: Others儲存式: Powder -80C 2 years-20C 1 yearIn solvent -80C 6 months-20C 1

2、month溶解性數(shù)據(jù)體外實(shí)驗(yàn) H2O : 135 mg/mL (235.36 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 1.7434 mL 8.7169 mL 17.4338 mL5 mM 0.3487 mL 1.7434 mL 3.4868 mL10 mM 0.1743 mL 0.8717 mL 1.7434 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 SLLK, Control Peptide fo

3、r TSP1 Inhibitor (TFA)板反應(yīng)蛋抑制劑 (TSP-1) LSKL 的對照肽。體內(nèi)研究Akita mice treated with 30 mg/kg LSKL have significantly increased nephrin expression, greater than twofold,compared with renal lysates from either saline controls or SLLK-treated mice 1.TGF-1 is significantly lower(0.100.01 pg/mL) in the plasma of

4、 mice receiving LSKL compared with that in plasma of mice receivingSLLK control peptide at day 42 (0.200.02 pg/mL; P=0.0001). MRNA expression is assessed in the1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEsuprarenal aortic lysates obtained from mice receiving SLLK and LSKL peptides 2.PROTOCOLAni

5、mal Mice 1Administration 1 The i.p. injection of LSKL, SLLK, or saline began 2 weeks after uninephrectomy and continues thrice weeklyfor 15 weeks. For the low-dosage treatment regimen, each group of 20 mice receives 3 mg/kg body weight ofpeptide (LSKL or SLLK) per injection or saline (100 L/10 g bod

6、y weight per injection). For the high-dosagetreatment regimen, Akita mice are given i.p. injections of LSKL or SLLK peptide at 30 mg/kg body weight perinjection or saline (100 L/10 g body weight per injection) 1.MCE has not independently confirmed the accuracy of these methods. They are for referenc

7、e only.REFERENCES1. Lu A, et al. Blockade of TSP1-dependent TGF- activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy.Am J Pathol. 2011 Jun;178(6):2573-86.2. Krishna SM, et al. A peptide antagonist of thrombospondin-1 promotes abdominal aortic aneurysm progression in the angiotensin II-infused apolipoprotein-E-deficient mouse. Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):389-98.McePdfHeightCaution: Product has not been fully validated for medical applications.For rese